Web Results



Bristol-Myers Squibb justified the high prices of cancer drugs with the high R&D costs, but the Union of Affordable Cancer ... Jump up ^ https://www.otsuka.co.jp/ en/company/release/2015/0302_01....

Case Project - American Antitrust Institute


Pan.Mult.Lit. Dec. 21,. 2004((No. MDL 1648). Page 84. In re Sorbates Direct ..... v. Bristol-Myers Squibb Co, et al, No. 01-CV. 11401, MDL 1413 (available at.

Blood Journal | Impact of comorbidities on overall survival in patients ...


Jul 2, 2015 ... ... of Hughes et al and Cross et al and were performed in standardized and accredited laboratories .... and Bristol Myers Squibb and received research funding by Bristol Myers Squibb and Novartis .... Nilotinib vs imatinib in patients with newly diagnosed Philadelphia .... Baccarani M,; Cortes J,; Pane F,; et al.

BCR-ABL1 mutation development during first-line treatment - Nature


Jul 21, 2015 ... Dasatinib patients had a narrower spectrum of mutations (4 vs 12 ..... TPH has received honoraria and research funding from ARIAD, Bristol-Myers Squibb ( BMS) and Novartis. ... Lawrence RM, Ho M, Irwin DL, Scott HS, Hughes TP et al. ..... AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, ...

Filko Prugo - LMG Life Sciences


Genzyme Corporation, et al. v. ... Bristol Myers Squibb adv. ... Trial counsel for BMS in an inventorship challenge by the University of Michigan and Repligen ...

Full Text


P < 0.0001 vs. placebo for all time points assessed. ..... LipoScience, and Alkermes; he holds stock in Bristol-Myers Squibb, Isis/Genzyme, Merck, Pfizer, Eli Lilly and Company, .... Alberti KG,; Eckel RH,; Grundy SM,; et al.,; International Diabetes Federation Task Force on Epidemiology and ... Pan XR,; Li GW,; Hu YH, ; et al.



Chimpanzees (Pan troglodytes) are the closest living relatives to humans, being ... In particular, chimpanzees have served as a model of human disease (Nath et al., 2000) and ... and development candidates from the Bristol-Myers Squibb Company (formerly .... The Vdss for theophylline was similar in two species ( Table 2).

Pharmacokinetic interaction between propranolol and the


'Bristol-Myers Squibb PharmaceuticalResearch Institute, New Brunswickand Princeton, NJ, and 2The Medical Centerat ... Krukemyer & Talbert, 1987; Nakaya et al., 1987; Pan et al. ... Insurance Co. standard tables-1986. .... pravastatin metabolites SQ 31,906 (the 3 a-hydroxy-isomeric metabolite-V) and SQ 31,945 ( the 3-oa, ...

Get PDF (168K) - Wiley Online Library


Feb 15, 2011 ... (Sprycel; Bristol-Myers Squibb Company, Princeton, NJ) increases .... Intolerance to TKI therapy/Pinilla-Ibarz et al. Cancer ..... Baccarani M, Cortes J, Pane F, et al. ... reporting by patients vs clinicians: relationships with clinical.

PLOS ONE: Impairment of Type I but Not Type III IFN Signaling by ...


Mar 31, 2015 ... All authors of this manuscript are employees of Bristol-Myers Squibb. ..... Transcriptional levels of type I and type III co-receptors, IFNAR2 and ..... In agreement with these findings, Chandra et al. recently showed in an ... Similarly, reduced efficacy against GT-3 has been observed with new pan-genotypic ...

Helpful Resources



BRISTOL-MYERS SQUIBB COMPANY v. APOTEX, INC. et al, No. ... BMS alleges that Apotex s 5 generic dasatinib tablet infringes the 746 Patent, the 875 Patent, the 856 Patent, and the 725 Patent. ...... (E.g., open pan, first run/second run).

Bristol-Myers Escapes $3.4B Apotex Suit Over Plavix Deal - Law360


Mar 14, 2013 ... Bristol-Myers Squibb Co. and partner Sanofi-Aventis SA won a defense verdict Wednesday in a $3.4 billion ... The case is Apotex Inc. et al. v.

The development of immunomodulatory monoclonal antibodies as a ...


Dec 1, 2014 ... Ipilimumab (Yervoy®, Bristol-Myers Squibb) and nivolumab (OPDIVO, Ono ... Many immune checkpoint or co-stimulatory molecules regulating the ... However, initially its function was not fully understood (Brunet et al., 1987). ..... 10.9 vs. 5.7 %), and progression-free survival (PFS) (with medians of 2.76 vs.

Bristol-Myers Seeks To Bust Genentech Cancer Drug ... - Mayer Brown


May 7, 2013 ... In a complaint, Bristol-Myers Squibb targeted Genentech Inc. and nonprofit cancer ... Hope are co-assignees of the patents, according to the suit. ... The case is Bristol-Myers Squibb Co. v. Genentech Inc. et al., case No.

Differential effects of dosing regimen on the safety and efficacy of ...


Jun 10, 2013 ... For example, Larson et al have shown the correlation of imatinib Cmin with both .... Sprycel<sup>®</sup>(dasatinib) [summary of product characteristics] Epernon: Bristol- Myers Squibb Company; 2012. 8. .... Baccarani M, Cortes J, Pane F, et al. ... et al. IRIS (International Randomized Interferon vs STI571) Study Group.